市場調查報告書
商品編碼
1541699
靜脈注射(IV) 布洛芬市場報告(依產品劑量(100 毫克劑量、200 毫克劑量、400 毫克劑量、800 毫克劑量)、適應症(疼痛/發炎、發燒)、年齡層(兒科、成人)和地區2024-2032Intravenous (IV) Ibuprofen Market Report by Product Dose (100 Mg Dose, 200 Mg Dose, 400 Mg Dose, 800 Mg Dose), Indication (Pain/Inflammatory, Fever), Age Group (Pediatrics, Adults), and Region 2024-2032 |
IMARC Group年,全球靜脈注射(IV)布洛芬市場規模達68億美元。 。
布洛芬屬於非類固醇類抗發炎藥 (NSAID),用於治療發炎、疼痛和發燒。它抑制合成前列腺素 (PG) 所需的環氧合酶 COZ-1 和 COX-2。靜脈注射 (IV) 布洛芬可單獨使用或與其他藥物一起使用,以緩解輕度至重度不適。它被直接注射到靜脈中,以阻止身體產生某些引起發炎的天然物質。它具有出色的安全性,有助於減少麻醉鎮痛需求並降低疼痛程度。靜脈注射布洛芬也有助於改善疼痛控制並減少骨科和腹部手術中鴉片類藥物的使用以及發燒。
全球範圍內老年人口的穩定成長以及關節炎、心血管疾病 (CVD) 和癌症患病率的不斷上升正在為市場創造積極的前景。與此一致的是,用於管理和治療發炎性疾病、類風濕性疾病、輕度至中度疼痛、發燒、經痛和骨關節炎的產品的廣泛採用有利於市場成長。此外,繁忙的工作日程和不健康的生活方式,以及隨之而來的體力活動和適當營養的減少,導致慢性病的發病率上升,這是另一個促進生長的因素。除此之外,兒科治療輕度發燒、牙痛、胃腸道疼痛和動脈導管的產品使用量不斷增加,也推動了市場成長。此外,靜脈注射布洛芬用於緩解肌肉或風濕疼痛、背痛、神經痛、扭傷、拉傷、運動傷害和肌肉骨骼疾病,這促進了市場成長。此外,骨科患者在膝關節或髖關節置換手術後對靜脈注射布洛芬的需求不斷增加,以減輕疼痛和嗎啡的使用,這對市場成長產生了積極影響。其他因素,包括醫療基礎設施的顯著改善、個人健康意識的增強以及消費者支出能力的提高,預計將推動市場成長。
The global intravenous (IV) ibuprofen market size reached US$ 6.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.79% during 2024-2032.
Ibuprofen belongs to the nonsteroidal anti-inflammatory drug (NSAID) class used to treat inflammation, pain, and fever. It inhibits cyclooxygenase COZ-1 and COX-2 enzymes that are required for the synthesis of prostaglandins (PG). Intravenous (IV) ibuprofen is used alone or with other medicines to relieve mild to severe discomfort. It is injected directly into the vein to block the body's production of certain natural substances that cause inflammation. It helps to reduce narcotic analgesic requirements and lower pain levels with an excellent safety profile. IV ibuprofen also aids in improving pain control and reducing the usage of opioid drugs in orthopedic and abdominal surgeries and fever.
The steadily rising geriatric population and the increasing prevalence of arthritis, cardiovascular diseases (CVDs), and cancer across the globe are creating a positive outlook for the market. In line with this, the widespread product adoption to manage and treat inflammatory diseases, rheumatoid disorders, mild to moderate pain, fever, dysmenorrhea, and osteoarthritis is favoring the market growth. Moreover, hectic working schedules and unhealthy lifestyles, along with a consequent decline in physical activity and proper nutrition, have led to a rise in the incidences of chronic diseases, which is acting as another growth-inducing factor. Apart from this, the increasing product utilization to treat mild fever, dental pain, gastrointestinal pain, and ductus arteriosus in pediatrics is providing an impetus to the market growth. Moreover, IV ibuprofen is employed to relieve muscle or rheumatic pain, backache, neuralgia, sprains, strains, sports injuries, and musculoskeletal diseases, which is facilitating the market growth. Furthermore, the increasing demand for IV ibuprofen in orthopedic patients post knee or hip replacement surgeries to reduce pain and morphine use is positively influencing the market growth. Other factors, including significant improvements in the healthcare infrastructure, growing health consciousness among individuals, and the rising expenditure capacities of consumers, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global intravenous (IV) ibuprofen market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product dose, indication and age group.
100 Mg Dose
200 Mg Dose
400 Mg Dose
800 Mg Dose
Pain/Inflammatory
Fever
Pediatrics
Adults
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Recordati Rare Diseases Inc., VALMOR Laboratories CA and Xgen Pharmaceuticals Djb Inc.